Globeimmune Inc
OTC:GBIM
Intrinsic Value
GlobeImmune, Inc. is a biopharmaceutical company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of GBIM.
Fundamental Analysis
Balance Sheet Decomposition
Globeimmune Inc
Current Assets | 9.4m |
Cash & Short-Term Investments | 8.7m |
Other Current Assets | 756k |
Non-Current Assets | 321.3k |
PP&E | 190.6k |
Other Non-Current Assets | 130.6k |
Current Liabilities | 4.1m |
Accounts Payable | 407.7k |
Accrued Liabilities | 286.7k |
Other Current Liabilities | 3.5m |
Non-Current Liabilities | 3.5m |
Other Non-Current Liabilities | 3.5m |
Earnings Waterfall
Globeimmune Inc
Revenue
|
6.2m
USD
|
Cost of Revenue
|
-127.2k
USD
|
Gross Profit
|
6.1m
USD
|
Operating Expenses
|
-8.2m
USD
|
Operating Income
|
-2.1m
USD
|
Other Expenses
|
0
USD
|
Net Income
|
-2.1m
USD
|
Free Cash Flow Analysis
Globeimmune Inc
What is Free Cash Flow?
GBIM Profitability Score
Profitability Due Diligence
Globeimmune Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Globeimmune Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
GBIM Solvency Score
Solvency Due Diligence
Globeimmune Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Globeimmune Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GBIM Price Targets Summary
Globeimmune Inc
Ownership
GBIM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
GBIM Price
Globeimmune Inc
Average Annual Return | 175.51% |
Standard Deviation of Annual Returns | 320.83% |
Max Drawdown | -100% |
Market Capitalization | 10.1k USD |
Shares Outstanding | 50 325 000 |
Percentage of Shares Shorted | 3.49% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
GlobeImmune, Inc. is a biopharmaceutical company. The company is headquartered in Louisville, Colorado. The company went IPO on 2014-07-02. The firm is engaged in development of products for the treatment of cancer and infectious diseases. The firm provides Tarmogen platform, which activate the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells, in contrast to traditional vaccines which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. The firm's oncology product candidates include GI-6301, GI-6207 and GI-4000. The firm's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.